{
    "clinical_study": {
        "@rank": "75615", 
        "acronym": "CGA-TAVI", 
        "arm_group": {
            "arm_group_label": "TAVI patients of > 79 years", 
            "description": "All patients undergoing transcatheter valve implantation with commercially available Edwards SAPIEN XT Transcatheter Heart Valve in participating sites.\nRoutine data about the intervention (transcatheter valve Implantation) will be collected. In addition, data describing the geriatric status of the patient, including a patient questionnaire evaluating his/her Quality of life will be collected."
        }, 
        "brief_summary": {
            "textblock": "Registry study to evaluate the predictive value of a comprehensive geriatric assessment with\n      regard to the outcome of a transcatheter aortic valve Implantation.\n\n      It will be evaluated which parts of the comprehensive geriatric assessment (CGA) are best\n      suited to predict the therapeutic success of a heart valve Implantation in elderly ( > 80\n      years) Patient. Possible participants are all Patient of 80 years or above for whom the\n      implantation of a Edwards Sapien XT aortic valve is planned"
        }, 
        "brief_title": "CGA-TAVI Registry to Evaluate the Predictive Value of a CGA in Predicting TAVI Outcomes", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Aortic Valve Stenosis", 
        "condition_browse": {
            "mesh_term": "Aortic Valve Stenosis"
        }, 
        "detailed_description": {
            "textblock": "Transcatheter Aortic Valve Implantation Registry with Comprehensive Geriatric Assessment"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Scheduled TAVI using Edwards SAPIEN XT Transcatheter Heart Valve\n\n          -  Compliance with the indications of the instructions for use\n\n          -  Age of at least 80 years\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Presence of contraindications as to the Instructions for Use\n\n          -  No possibility for a follow-up"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "80 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All patients undergoing transcatheter valve implantation with commercially available\n        Edwards SAPIEN XT Transcatheter Heart Valve in participating sites.\n\n        Routine data about the invervention (transcatheter valve Implantation) will be collected.\n        In addition, data describing the geriatric status of the patient, including a patient\n        questionnaire evaluating his/her Quality of life will be collected."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991444", 
            "org_study_id": "U1111-1149-9951", 
            "secondary_id": "DRKS00005436"
        }, 
        "intervention": {
            "arm_group_label": "TAVI patients of > 79 years", 
            "description": "no Intervention planned, Observation only", 
            "intervention_name": "TAVI", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany"
                    }, 
                    "name": "University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Nikos Werner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiel", 
                        "country": "Germany"
                    }, 
                    "name": "Universit\u00e4tsklinikum Kiel"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rozzini-renzo@poliambulanza.it", 
                    "last_name": "Renzo Rozzini, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Brescia", 
                        "country": "Italy", 
                        "zip": "25124"
                    }, 
                    "name": "Fondazione Poliambulanza Istituto Ospedaliero"
                }, 
                "investigator": {
                    "last_name": "Renzo Rozzini, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Florence", 
                        "country": "Italy"
                    }, 
                    "name": "University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Andrea Ungar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Germany", 
                "Italy"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Registry Study to Evaluate the Predictive Value of a Comprehensive Geriatric Assessment With Regard to the Outcome of a Transcatheter Aortic Valve Implantation.", 
        "overall_contact": {
            "email": "peter.bramlage@ippmed.de", 
            "last_name": "Peter Bramlage, MD", 
            "phone": "+494471850", 
            "phone_ext": "3339"
        }, 
        "overall_contact_backup": {
            "email": "kerstin.plate@ippmed.de", 
            "last_name": "Kerstin Plate", 
            "phone": "+494471850", 
            "phone_ext": "3331"
        }, 
        "overall_official": {
            "affiliation": "Geriatric Cardiology and Medicine - U. of  Florence", 
            "last_name": "Andrea Ungar, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Demonstrate CGA changes within 3 months after TAVI\nThe CGA is an array of several different assessments with regard to frailty, comorbidities, administrative data (Silver code), Quality of life etc. Every Patient will undergo a CGA at baseline and 3 months after TAVI. Data will be analyzed to determine changes in CGA results.", 
            "measure": "Comprehensive geriatric assessment", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991444"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Establish predictive value of CGA (MPI, SPPB, SilverCode) in TAVI patients for all-cause hospitalization, TAVI related hospitalization, nursing home admission", 
                "measure": "predictive Value of CGA Tavi", 
                "safety_issue": "No", 
                "time_frame": "baseline"
            }, 
            {
                "description": "Development of a comprehensive score for the assessment of TAVI patient prognosis (identifying variables from the MPI, SPPB and SilverCode that account for 80% of the predictive power of the complete set)", 
                "measure": "Score development", 
                "safety_issue": "No", 
                "time_frame": "after 3 months"
            }
        ], 
        "source": "Institut f\u00fcr Pharmakologie und Pr\u00e4ventive Medizin", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institut f\u00fcr Pharmakologie und Pr\u00e4ventive Medizin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "12 Months", 
        "verification_date": "May 2014"
    }
}